A comprehensive review on sodium glucose Co-transporter-2 inhibitors-empagliflozin Arun Sanjaana1, Praveen D2, Chowdary Ranadheer P2, Aanandhi Vijey M3,* 1School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advance Studies (VISTAS), Chennai, Tamil Nadu, India 2Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advance Studies (VISTAS), Chennai, Tamil Nadu, India 3Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advance Studies (VISTAS), Chennai, Tamil Nadu, India *Corresponding Author E-mail: hodpchemistry@velsuniv.ac.in
Online published on 20 February, 2023. Abstract Diabetes is one of the most common global illness affecting millions of people in the world. SGLT2 is newly classified anti-diabetic drug, it is highly selective novel approach for type -II diabetes patients because it as low affinity to plasma proteins and high capacity transport of glucose protein compared to SGLT1. Empagliflozin is highly selective for SGLT2, which is sold under the brand name of Jardiance it is mainly recommended for type II DM. The studies have proven that empagliflozin shows both Cardio protective and Reno protective effects and well established for the management of weight loss in diabetes mellitus. Pharmacokinetic studies are well achieved and shown no major drug interactions and less side effects. SGLT2 inhibitors have given novel approach about orally administered drug and more or less this can benefit the patients for easy life style without leading to further complications. Top Keywords Anti-diabetic drug, Empagliflozin, SGLT2 inhibitors, Cardio protective and Reno protective. Top |